CoChat

Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Aims/hypothesis Recently, incretin-related agents have been reported to attenuate insulin resistance in animal models, although the underlying mechanisms remain unclear. In this study, we investigated whether anagliptin, the dipeptidyl peptidase 4 (DPP-4) inhibitor, attenuates skeletal muscle insulin resistance through endothelial nitric oxide synthase (eNOS) activation in the endothelial cells. We used endothelium-specific Irs2-knockout (ETIrs2KO) mice, which show skeletal muscle insulin resistance resulting from a reduction of insulin-induced skeletal muscle capillary recruitment as a consequence of impaired eNOS activation.Methods In vivo, 8-week-old male ETIrs2KO mice were fed regular chow with or without 0.3% (wt/wt) DPP-4 inhibitor for 8 weeks to assess capillary recruitment and glucose uptake by the skeletal muscle. In vitro, human coronary arterial endothelial cells (HCAECs) were used to explore the effect of glucagon-like peptide 1 (GLP-1) on eNOS activity.Results Treatment with anagliptin ameliorated the impaired insulin-induced increase in capillary blood volume, interstitial insulin concentration and skeletal muscle glucose uptake in ETIrs2KO mice. This improvement in insulin-induced glucose uptake was almost completely abrogated by the GLP-1 receptor (GLP-1R) antagonist exendin-(9-39). Moreover, the increase in capillary blood volume with anagliptin treatment was also completely inhibited by the NOS inhibitor. GLP-1 augmented eNOS phosphorylation in HCAECs, with the effect completely disappearing after exposure to the protein kinase A (PKA) inhibitor H89. These data suggest that anagliptin treatment enhances insulin-induced capillary recruitment and interstitial insulin concentrations, resulting in improved skeletal muscle glucose uptake by directly acting on the endothelial cells via NO- and GLP-1-dependent mechanisms in vivo.Conclusions/interpretation Anagliptin may be a promising agent to ameliorate skeletal muscle insulin resistance in obese patients with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-016-4071-8

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Sunami Y, Sesoko S, Kaku K (2012) Pharmacokinetics and pharmacodynamics of single and multiple doses of anagliptin, a novel inhibitor of dipeptidyl peptidase-4. Jpn Pharmacol Ther 40:847–858 [article in Japanese]

Cited by

See all 20

Metadata

Authors
Sato, H., Kubota, N., Kubota, T., Takamoto, I., Iwayama, K., Tokuyama, K., Moroi, M., Sugi, K., Nakaya, K., Goto, M., Jomori, T., & Kadowaki, T.
Affiliations
  • The University of Tokyo (JP)
  • RIKEN Center for Integrative Medical Sciences (JP)
  • Toho University Ohashi Medical Center (JP)
  • University of Tsukuba (JP)
  • Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
Corresponding author
  • Kubota, Naoto
  • Kadowaki, Takashi
Venue
Diabetologia
Published
2016-08-15
Volume
59
Issue
11
Pages
2426-2434
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2512856880
Cited by
19
References
40
Citations by year
2025: 1 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 3
FWCI
2.35
Type
journal article
Language
en
Open access
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology (20229008, 18209033, 19591037, 16209030, 21390279)
  • Japan Society for the Promotion of Science (15H04847, 26000012)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
Keywords
anagliptin, DPP-4 inhibitors, skeletal muscle insulin resistance, endothelial nitric oxide synthase, nitric oxide, endothelial cells, capillary recruitment, glucagon-like peptide-1, GLP-1 receptor, protein kinase A, type 2 diabetes, obesity
MeSH terms
Animals, Insulin, Insulin Resistance, Male, Nitrogen Oxides, Pyrimidines, Muscle, Skeletal, Dipeptidyl Peptidase 4, Endothelial Cells, Mice, Nitric Oxide Synthase Type III, Tandem Mass Spectrometry, Dipeptidyl-Peptidase IV Inhibitors, Insulin Receptor Substrate Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice. https://app.cochat.ai/papers/10.1007/s00125-016-4071-8
The paper
Sato, H., Kubota, N., Kubota, T., Takamoto, I., Iwayama, K., Tokuyama, K., Moroi, M., Sugi, K., Nakaya, K., Goto, M., Jomori, T., & Kadowaki, T. (2016). Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice. Diabetologia. https://doi.org/10.1007/s00125-016-4071-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.